Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Kenneth M. Wyatt x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To retrospectively assess the safety and efficacy of recombinant human granulocyte colony-stimulating factor (G-CSF) used as part of autologous bone marrow transplantation in dogs with lymphoma.

Animals—21 dogs with lymphoma at any disease stage.

Procedures—Medical records of dogs with lymphoma that underwent intensified chemotherapy and received an autologous bone marrow transplant following owner administration of recombinant human G-CSF (5 μg/kg, SC, q 12 h) for 7 days between January 2007 and July 2009 were reviewed. Results of physical examinations and CBCs performed before and at intervals during a 24-month period after G-CSF treatment were assessed. The safety of recombinant human G-CSF administration was determined via assessment of both short-term (ie, during the 7-day G-CSF treatment period) and long-term adverse effects.

Results—None of the dogs developed any adverse effect attributable to the administration of recombinant human G-CSF during G-CSF administration or during follow-up periods of 1 month to 2 years (median follow-up period, 4 months). Among the 18 dogs for which CBC results were available for analysis, mean circulating neutrophil count significantly increased after administration of recombinant human G-CSF, compared with value before treatment.

Conclusions and Clinical Relevance—Results indicated that recombinant human G-CSF administered SC at a dosage of 5 μg/kg every 12 hours for 7 days appeared to be safe and effective when used in dogs with lymphoma that were undergoing autologous bone marrow transplant.

Full access
in American Journal of Veterinary Research

Abstract

Objective—To determine accuracy of a manual technique for detection of neutropenia and thrombocytopenia in dogs receiving chemotherapy.

Design—Masked prospective study.

Animals—11 dogs treated with chemotherapy for neoplasia.

Procedure—124 blood samples from dogs being treated with chemotherapy for various neoplasms were processed through an automated cell counter, and results were compared with those obtained by use of a rapid manual technique for estimating neutrophil and platelet concentrations to determine whether the manual technique could accurately detect dogs with neutropenia or thrombocytopenia.

Results—By use of automated techniques, neutropenia (< 3,000 cells/µl) was detected in 17 of 124 blood samples, and thrombocytopenia (< 100,000 platelets/µl) was detected in 3 of 124 blood samples. The manual technique correctly identified 16 of 17 (94%) blood samples with neutropenia, with a specificity of 92% (98/107). The manual technique correctly identified 3 of 3 (100%) blood samples with thrombocytopenia, with specificity of 94% (114/121).

Conclusions and Clinical Relevance—Manual estimates of neutrophil and platelet counts are sensitive and specific; however, a full differential cell count is still preferable. (J Am Vet Med Assoc 2002;220:1805–1806)

Full access
in Journal of the American Veterinary Medical Association